Kindred Biosciences Inc is a US-based development-stage biopharmaceutical company which focuses on developing medicines for pets. Its lead products candidates are the intravenous (IV) form of Zimeta which is a dipyrone injection for the control of pyrexia in horses and Mirataz which is a mirtazapine transdermal ointment for the management of weight loss in cats. The product pipeline of the company consists of small molecules and biologics for a range of indications in dogs, cats, and horses, with focus near-term on equine small molecule products and canine and feline biologics products.